These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 38093344)

  • 1. Considerations for the genotoxicity assessment of middle size peptide drugs containing non-canonical amino acid residues.
    Mishima M; Sugiyama KI
    Genes Environ; 2023 Dec; 45(1):36. PubMed ID: 38093344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genotoxicity assessment of peptide/protein-related biotherapeutics: points to consider before testing.
    Thybaud V; Kasper P; Sobol Z; Elhajouji A; Fellows M; Guerard M; Lynch AM; Sutter A; Tanir JY
    Mutagenesis; 2016 Jul; 31(4):375-84. PubMed ID: 27000792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genotoxicity testing: current practices and strategies used by the pharmaceutical industry.
    Purves D; Harvey C; Tweats D; Lumley CE
    Mutagenesis; 1995 Jul; 10(4):297-312. PubMed ID: 7476265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. International regulatory requirements for genotoxicity testing for pharmaceuticals used in human medicine, and their impurities and metabolites.
    Galloway SM
    Environ Mol Mutagen; 2017 Jun; 58(5):296-324. PubMed ID: 28299826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ICH-harmonised guidances on genotoxicity testing of pharmaceuticals: evolution, reasoning and impact.
    Müller L; Kikuchi Y; Probst G; Schechtman L; Shimada H; Sofuni T; Tweats D
    Mutat Res; 1999 May; 436(3):195-225. PubMed ID: 10354523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How to reduce false positive results when undertaking in vitro genotoxicity testing and thus avoid unnecessary follow-up animal tests: Report of an ECVAM Workshop.
    Kirkland D; Pfuhler S; Tweats D; Aardema M; Corvi R; Darroudi F; Elhajouji A; Glatt H; Hastwell P; Hayashi M; Kasper P; Kirchner S; Lynch A; Marzin D; Maurici D; Meunier JR; Müller L; Nohynek G; Parry J; Parry E; Thybaud V; Tice R; van Benthem J; Vanparys P; White P
    Mutat Res; 2007 Mar; 628(1):31-55. PubMed ID: 17293159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strategy for genotoxicity testing--metabolic considerations.
    Ku WW; Bigger A; Brambilla G; Glatt H; Gocke E; Guzzie PJ; Hakura A; Honma M; Martus HJ; Obach RS; Roberts S;
    Mutat Res; 2007 Feb; 627(1):59-77. PubMed ID: 17141553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of genotoxicity testing of FDA approved large molecule therapeutics.
    Sawant SG; Fielden MR; Black KA
    Regul Toxicol Pharmacol; 2014 Oct; 70(1):87-97. PubMed ID: 24932799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genotoxicity test battery - An assessment of its utility in early drug development.
    Baldrick P
    Mutat Res Genet Toxicol Environ Mutagen; 2021; 868-869():503388. PubMed ID: 34454694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the ability of a battery of three in vitro genotoxicity tests to discriminate rodent carcinogens and non-carcinogens II. Further analysis of mammalian cell results, relative predictivity and tumour profiles.
    Kirkland D; Aardema M; Müller L; Makoto H
    Mutat Res; 2006 Sep; 608(1):29-42. PubMed ID: 16769241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Follow-up genotoxicity assessment of Ames-positive/equivocal chemicals using the improved thymidine kinase gene mutation assay in DNA repair-deficient human TK6 cells.
    Sassa A; Fukuda T; Ukai A; Nakamura M; Sato R; Fujiwara S; Hirota K; Takeda S; Sugiyama KI; Honma M; Yasui M
    Mutagenesis; 2021 Oct; 36(5):331-338. PubMed ID: 34216473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How to assess the mutagenic potential of cosmetic products without animal tests?
    Speit G
    Mutat Res; 2009 Aug; 678(2):108-12. PubMed ID: 19379833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulatory requirements for genotoxicity assessment of plant protection product active ingredients, impurities, and metabolites.
    Booth ED; Rawlinson PJ; Maria Fagundes P; Leiner KA
    Environ Mol Mutagen; 2017 Jun; 58(5):325-344. PubMed ID: 28329407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of published data for top concentration considerations in mammalian cell genotoxicity testing.
    Parry JM; Parry E; Phrakonkham P; Corvi R
    Mutagenesis; 2010 Nov; 25(6):531-8. PubMed ID: 20720196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the ability of a battery of three in vitro genotoxicity tests to discriminate rodent carcinogens and non-carcinogens I. Sensitivity, specificity and relative predictivity.
    Kirkland D; Aardema M; Henderson L; Müller L
    Mutat Res; 2005 Jul; 584(1-2):1-256. PubMed ID: 15979392
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Update on genotoxicity and carcinogenicity testing of 472 marketed pharmaceuticals.
    Brambilla G; Martelli A
    Mutat Res; 2009; 681(2-3):209-229. PubMed ID: 18845271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Testing strategies in mutagenicity and genetic toxicology: an appraisal of the guidelines of the European Scientific Committee for Cosmetics and Non-Food Products for the evaluation of hair dyes.
    Kirkland DJ; Henderson L; Marzin D; Müller L; Parry JM; Speit G; Tweats DJ; Williams GM
    Mutat Res; 2005 Dec; 588(2):88-105. PubMed ID: 16326131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of the sensitivity of the computational programs DEREK, TOPKAT, and MCASE in the prediction of the genotoxicity of pharmaceutical molecules.
    Snyder RD; Pearl GS; Mandakas G; Choy WN; Goodsaid F; Rosenblum IY
    Environ Mol Mutagen; 2004; 43(3):143-58. PubMed ID: 15065202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of "Big Data" to Evaluate Responses to Changes in Regulatory Guidelines: Trends in Genotoxicity Testing Packages for New Pharmaceutical Products.
    Reeve L; Baldrick P; Newell A; Templeton S
    Ther Innov Regul Sci; 2020 Jul; 54(4):764-769. PubMed ID: 32557294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.